All In Biotech

Drug Trial Radar · NCT07321912

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

406

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Jun 1, 2031

Study completion Jun 1, 2036

Sponsor

Lead sponsor
Milton S. Hershey Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
USWM, LLC (dba US WorldMeds)
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.

Conditions

  • Osteosarcoma
  • Ewing Sarcoma

Interventions

  • EflornithineDrug

    Oral twice daily

  • TopotecanDrug

    IV

  • CyclophosphamideDrug

    IV

  • VincristineDrug

    IV

  • DoxorubicinDrug

    IV

  • IfosfamideDrug

    IV

  • EtoposideDrug

    IV

  • CisplatinDrug

    IV

  • MethotrexateDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Cohort 1 participants with relapse free survival (RFS) during studyTime frame: 2 years plus 5 years follow up
  2. Number of Cohort 2 participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up
  3. Cohort 3: Number of Cohort 3 participants at 12 months with disease controlTime frame: 1 year plus 5 years follow up
  4. Cohort 4A: Number of Cohort 4A participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up
  5. Cohort 4B: Number of Cohort 4B participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph's Children's Hospital

    Tampa, Florida · Recruiting

  • Randall Children's Hospital

    Portland, Oregon · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.